Atrial Fibrillation, Acute Coronary Syndromes
Conditions
Brief summary
The study aims to show inferiority of rivaroxaban plus ticagrelor when compared to rivaroxaban plus clopidogrel in terms of safety. Safety will be determined by comparing the rates of death or ischemic event-including myocardial infarction, definite or probable stent thrombosis, stroke, or urgent revascularization.
Detailed description
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of rivaroxaban plus ticagrelor with rivaroxaban plus clopidogrel in Patients With Non Valvular Atrial Fibrillation (NVAF) and Acute Coronary Syndrome. The study aims to show inferiority of rivaroxaban plus ticagrelor when compared to rivaroxaban plus clopidogrel in terms of safety. Safety will be determined by comparing the rates of death or ischemic event-including myocardial infarction, definite or probable stent thrombosis, stroke, or urgent revascularization.
Interventions
DRUGRivaroxaban 15 MG Oral Tablet
One 15 mg tablet once daily for up to twelve months
One 75 mg tablet once daily for up to twelve months
One 90 mg tablet twice daily for up to twelve months
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
1. Adults with either active or a history of non-valvular atrial fibrillation or flutter with the planned or existing use of an oral anticoagulant for prophylaxis of thromboembolism. In addition, subjects must have had an acute coronary syndrome 2. Planned use of antiplatelet agents for at least 12 months 3. Males and Females ≥ 18 years of age 4. Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug
Exclusion criteria
1. Conditions other than atrial fibrillation that require chronic anticoagulation. (e.g. prosthetic mechanical heart valve) 2. Severe renal insufficiency (serum creatinine \> 2.5 mg/dL or a calculated creatinine clearance \< 30 mL/min 3. Patients with a history of intracranial hemorrhage 4. Patients have had or will undergo Coronary arterial bypass graft (CABG) for their index acute coronary syndrome (ACS) event 5. Patients with known ongoing bleeding and patients with known coagulopathies 6. Any contraindications or allergies to rivaroxaban, or to intended P2Y12 antagonists 7. Have a history of stroke or Transient Ischemic Attack (TIA) 8. Have known significant liver disease or liver function test (LFT) abnormalities 9. Have any severe condition that would limit life expectancy to less than 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The composite endpoints of death and ischemic events | one year | The composite endpoints of death and ischemic events (stroke, myocardial infarction, stent thrombosis, urgent revascularization ) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinically significant bleeding | one year | Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA) |
Contacts
Primary ContactJun Jiang, PhD
Outcome results
None listed